ANI Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 642
- Market Cap
- $1.3B
- Introduction
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.
Uveitis and Optic Neuritis Markets Set for Major Growth Through 2034 as New Therapies Advance
The global uveitis treatment market reached approximately $1.47 billion in 2022 across seven major markets and is projected to grow significantly through 2034, driven by emerging therapies and expanded treatment indications.
FDA Approves ILUVIEN Label Expansion for Chronic Non-Infectious Uveitis Treatment
The FDA has approved an expanded label for ILUVIEN (fluocinolone acetonide intravitreal implant) to include treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, in addition to its existing diabetic macular edema indication.
FDA Approves ANI Pharmaceuticals' Cortrophin Gel Prefilled Syringe for Multiple Autoimmune Conditions
ANI Pharmaceuticals receives FDA approval for a new prefilled syringe format of Cortrophin Gel, available in 40 USP units/0.5 mL and 80 USP units/mL single-dose options.
ANI Pharmaceuticals Launches Prucalopride Tablets for Chronic Idiopathic Constipation with 180-Day Exclusivity
ANI Pharmaceuticals has launched Prucalopride Tablets, a generic version of Motegrity, after receiving FDA approval and a Competitive Generic Therapy (CGT) designation.
ANI Pharmaceuticals Launches Estradiol Gel, 0.06% Following FDA Approval
ANI Pharmaceuticals has launched Estradiol Gel, 0.06%, after receiving final FDA approval for its Abbreviated New Drug Application, expanding its product portfolio.
ANI Pharmaceuticals Launches Generic Estradiol Gel Following FDA Approval
ANI Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA) for Estradiol Gel, 0.06%, a generic version of EstroGel.
ANI Pharmaceuticals Launches Generic Estradiol Gel, 0.06% Following FDA Approval
ANI Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA) for Estradiol Gel, 0.06%, a generic version of EstroGel.
ANI Pharmaceuticals Launches Generic Estradiol Gel, 0.06% Following FDA Approval
ANI Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA) for Estradiol Gel, 0.06%, a generic version of EstroGel.
ANI Pharmaceuticals Launches Ketoconazole Shampoo, 2% Following FDA Approval
ANI Pharmaceuticals has received FDA approval and launched Ketoconazole Shampoo, 2%, a generic version of Nizoral®, marking another limited competition product.